• Aucun résultat trouvé

18 résultats avec le mot-clé: 'dendrogenin synergizes cytarabine acute myeloid leukemia cells vitro'

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo

In addition, to trigger cancer cell re-differentiation, longer exposure times or µ M concentrations of DDA induced cell death in cancer cells of various tissue origins

Protected

N/A

17
0
0
2021
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; BAT, Bispecific antibody armed activated T-cells; BCMA, B-cell

Protected

N/A

20
0
0
2021
In vivo and in vitro sensitivity of Blastic Plasmacytoid Dendritic Cell Neoplasm to SL- 401, an interleukin-3 receptor targeted biologic agent Fanny Angelot-Delettre

18 Table 2: Expression of IL-3Rα and β chains on primary malignant cells from patients suffering from BPDCN, acute myeloid leukemia (AML) cells, acute lymphoid leukemia

Protected

N/A

20
0
0
2022
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Keywords: lipid nanocapsules, acute myeloid leukemia, decitabine, nanomedicine, nanopar- ticles, oral administration, Caco2

Protected

N/A

16
0
0
2022
Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia

Primary AML cells treated with DDA–idarubicin showed a massive accumulation of cytoplasmic macrovesicles visualized by MGG staining (Figure 4 B) and increased in MOLM-14, OCI-AML3

Protected

N/A

15
0
0
2021
Natural killer cells modulation in hematological malignancies

MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; CML, chronic myelogenous leukemia; ALL, acute

Protected

N/A

9
0
0
2021
ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration

ACKR3, atypical chemokine receptor 3; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CFP, cyan fluorescent protein; CNS, central nervous

Protected

N/A

17
0
0
2021
Polymorphismes dans des gènes de métabolisme des corticostéroïdes : rôle dans la réponse thérapeutique

polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. Prognostic significance ofthe null genotype of glutathione S-transferase-T1 in patients with acute

Protected

N/A

109
0
0
2021
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT

Abbreviations: ALWP, Acute leukemia working party; AML, Acute myeloid leukemia; ATT, Average treatment effect among the treated; auto-HSCT, Autologous stem cell transplantation;

Protected

N/A

15
0
0
2021
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT.

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ATG: Anti- thymocyte globulin; CB: Umbilical cord blood; CBT: Umbilical cord blood transplantation; CI:

Protected

N/A

11
0
0
2021
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ATG: Anti- thymocyte globulin; CB: Umbilical cord blood; CBT: Umbilical cord blood transplantation; CI:

Protected

N/A

12
0
0
2021
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiolo

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia

Protected

N/A

8
0
0
2021
Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute

Protected

N/A

22
0
0
2021
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia

Protected

N/A

12
0
0
2021
Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells -high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered

Protected

N/A

19
0
0
2021
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC

The impact of graft-versus-host disease prophylaxis in reduced- intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia

Protected

N/A

11
0
0
2021
The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia

Overall survival among (A) adults patients, (B) children, (C) patients with acute lymphoid leukemia, and (D) with acute myeloid leukemia according to the sequence of

Protected

N/A

7
0
0
2021

Télécharger plus de documents et télécharger des études de documentation immédiatement !